Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers
- PMID: 1475232
- DOI: 10.1023/a:1015862930096
Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers
Abstract
The pharmacokinetics and cardiovascular effects of nicotine and its major metabolite, cotinine, were characterized during repeated once-daily application for 5 days of a 30-cm2 nicotine transdermal system, Nicotine TTS (Habitrol), to nine healthy, black, adult, male smokers. Subjects abstained from smoking throughout the study. Pharmacokinetic analysis indicated that nicotine was delivered from Nicotine TTS for the 24-hr application period averaging 0.76 mg/cm2/24 hr, and at a relatively constant rate compared to other modes of drug administration. The transdermal clearance of nicotine, 1351 ml/min, coincided with reported values following intravenous nicotine administration; however, the terminal-phase half-life, 5.0 hr, did not. An analysis of the components of variance contributing to the variability in nicotine delivery from repetitive application of Nicotine TTS indicated that the in vivo transdermal permeation of nicotine is rate limited by both the device and the intrinsic skin conductivity. Clinical cardiovascular side effects were negligible as an apparent result of subclinical vasopressive nicotine concentrations, although drug activity with regard to other effects was manifested.
Similar articles
-
Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.Br J Clin Pharmacol. 1997 Mar;43(3):259-67. doi: 10.1111/j.1365-2125.1997.00566.x. Br J Clin Pharmacol. 1997. PMID: 9088580 Free PMC article. Clinical Trial.
-
Pharmacokinetics of multiple daily transdermal doses of nicotine in healthy smokers.Pharm Res. 1991 Mar;8(3):385-8. doi: 10.1023/a:1015810019076. Pharm Res. 1991. PMID: 2052530
-
Comparison of the nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) and half-hourly cigarette smoking.J Clin Pharmacol. 1995 Oct;35(10):985-9. doi: 10.1002/j.1552-4604.1995.tb04014.x. J Clin Pharmacol. 1995. PMID: 8568016 Clinical Trial.
-
Bioavailability and absorption kinetics of nicotine following application of a transdermal system.Br J Clin Pharmacol. 1993 Sep;36(3):221-7. doi: 10.1111/j.1365-2125.1993.tb04221.x. Br J Clin Pharmacol. 1993. PMID: 9114908 Free PMC article. Clinical Trial.
-
Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System).J Clin Pharmacol. 1993 Feb;33(2):161-8. doi: 10.1002/j.1552-4604.1993.tb03938.x. J Clin Pharmacol. 1993. PMID: 8440766 Clinical Trial.
Cited by
-
Optimisation of treatment by applying programmable rate-controlled drug delivery technology.Clin Pharmacokinet. 2002;41(15):1267-99. doi: 10.2165/00003088-200241150-00003. Clin Pharmacokinet. 2002. PMID: 12452738 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources